Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Pipeline Monitor
Second new biological for lipids
Repatha has followed hot on the heels of rival Praluent in gaining FDA approval, while diabetes and cancer combos and rare disease drugs have also enjoyed success.
Working Life
Candidate-short market plagues recruiters
A lack of suitable candidates to fill agency-advertised roles in the Australian pharma market was the major issue to emerge from a survey of pharma company use of external recruitment firms.
Approvals Action
Generics, OTCs make the running
The generics and over-the-counter ectors made the running on the drugs register during the week, which was a quiet one for new prescription drug approvals.
PBS Top Five
Rheumatology & MSK: a fast-growing market
The market for PBS subsidised rheumatology and musculoskeletal drugs is growing at close to 11 per cent a year according to the latest figures with on-patent drugs growing even faster at 16 per cent.
Special Report
Your guide to the November PBAC
The PBAC will consider 33 major submissions including 18 for new listings when it next meets in November. See the full agenda, sorted by indication, inside.